minimal Common Oncology Data Elements (mCODE) Implementation Guide, published by HL7 International / Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 4.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-mCODE-ig/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: cancer-related-medication-admin-doxorubicin-jenny-m - JSON Representation

Raw json | Download

{
  "resourceType" : "MedicationAdministration",
  "id" : "cancer-related-medication-admin-doxorubicin-jenny-m",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: MedicationAdministration cancer-related-medication-admin-doxorubicin-jenny-m</b></p><a name=\"cancer-related-medication-admin-doxorubicin-jenny-m\"> </a><a name=\"hccancer-related-medication-admin-doxorubicin-jenny-m\"> </a><a name=\"cancer-related-medication-admin-doxorubicin-jenny-m-en-US\"> </a><p><b>Normalization Basis Extension</b>: <span title=\"Codes:{http://snomed.info/sct 363804004}\">Body weight characteristic (observable entity)</span></p><p><b>status</b>: Completed</p><p><b>category</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/medicationrequest-category outpatient}\">Outpatient</span></p><p><b>medication</b>: <span title=\"Codes:{http://www.nlm.nih.gov/research/umls/rxnorm 1790099}\">10 ML doxorubicin hydrochloride 2 MG/ML Injection</span></p><p><b>subject</b>: <a href=\"Patient-cancer-patient-jenny-m.html\">Jenny M  Female, DoB: 1965-01-01 ( Medical Record Number: MRN1234\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>effective</b>: 2018-04-22</p><h3>Performers</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Actor</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"Practitioner-us-core-practitioner-nancy-oncology-nurse.html\">Practitioner Nancy Nurse </a></td></tr></table><p><b>reasonReference</b>: <a href=\"Condition-primary-cancer-condition-jenny-m.html\">Condition Primary malignant neoplasm of female left breast (disorder)</a></p><p><b>request</b>: <a href=\"MedicationRequest-cancer-related-medication-request-doxorubicin-jenny-m.html\">MedicationRequest: extension = Curative - procedure intent (qualifier value); status = active; intent = order; category = Outpatient; medication[x] = DOXOrubicin; authoredOn = 2018-04-12</a></p><p><b>note</b>: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)</p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td><td><b>Dose</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://snomed.info/sct 47625008}\">Intravenous route (qualifier value)</span></td><td>105.96 mg<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM  codemg = 'mg')</span></td></tr></table></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-normalization-basis",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "363804004",
            "display" : "Body weight characteristic (observable entity)"
          }
        ]
      }
    }
  ],
  "status" : "completed",
  "category" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
        "code" : "outpatient"
      }
    ]
  },
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "1790099",
        "display" : "10 ML doxorubicin hydrochloride 2 MG/ML Injection"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/cancer-patient-jenny-m"
  },
  "effectiveDateTime" : "2018-04-22",
  "performer" : [
    {
      "actor" : {
        🔗 "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      }
    }
  ],
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-jenny-m"
    }
  ],
  "request" : {
    🔗 "reference" : "MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"
  },
  "note" : [
    {
      "authorReference" : {
        🔗 "reference" : "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      },
      "time" : "2018-04-22",
      "text" : "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage" : {
    "route" : {
      "coding" : [
        {
          "system" : "http://snomed.info/sct",
          "code" : "47625008",
          "display" : "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose" : {
      "value" : 105.96,
      "unit" : "mg",
      "system" : "http://unitsofmeasure.org",
      "code" : "mg"
    }
  }
}